AstraZeneca Nexium Cleared For Lowering Risk Of NSAID-Related Ulcers
This article was originally published in The Tan Sheet
Executive Summary
A supplemental approval for Nexium will allow AstraZeneca to position the proton pump inhibitor as an alternative to switching patients to a COX-2 to reduce the risk of gastric ulcers associated with continuous NSAID therapy
You may also be interested in...
PPI Marketers Target Patients Leaving COX-2s For NSAIDs
Proton pump inhibitor marketers are poised to benefit from potential cardiovascular risk warnings for COX-2 inhibitors that could increase the migration of arthritis patients to traditional NSAIDs
PPI Marketers Target Patients Leaving COX-2s For NSAIDs
Proton pump inhibitor marketers are poised to benefit from potential cardiovascular risk warnings for COX-2 inhibitors that could increase the migration of arthritis patients to traditional NSAIDs
PPI Marketers Target Patients Leaving COX-2s For NSAIDs
Proton pump inhibitor marketers are poised to benefit from potential cardiovascular risk warnings for COX-2 inhibitors that could increase the migration of arthritis patients to traditional NSAIDs